RAPID Platform

Jnana has built the first drug discovery platform that targets SLC transporters, overcoming the myriad of challenges for addressing this target class.

Selection of the right target and identification of optimal chemical leads are the two most critical factors in the success of any small molecule drug discovery and development program.

Jnana prioritizes the selection of targets supported by human biology, including genome-wide association studies, monogenic diseases, and single-cell expression profiling of human tissues in health and disease.

At Jnana, we believe that pharmacological validation of a target using tool compounds in a patient-relevant assay system should happen as early as possible as it substantially increases the probability of program success.

However, the identification of tool compounds suitable for target validation and generation of chemical leads has historically been a slow and resource intensive endeavor that can only be pursued after a target has been thoroughly validated by genetic experiments.  This challenge shaped Jnana’s early pursuit of a new approach to drug discovery for SLC transporters.

RAPID identification of small-molecule binders in live cells

Jnana has built a proprietary ligand discovery platform called Reactive Affinity Probe Interaction Discovery (RAPID) that is carried out in live cells and enables the identification of chemical starting points for programs within weeks.

RAPID is a ‘plug-and-play’ technology that identifies binders irrespective of the fold or function of the target protein, delivering high quality, chemical matter for targets of interest. RAPID is ideally suited for SLC transporters which are highly diverse based on structure and cellular location, often difficult to express and purify, are not readily amenable to biophysical methods, and may have no known ligands.

Because RAPID identifies small molecules based only on their ability to bind the protein, it provides an unbiased approach for tackling challenging SLC targets. Binders are valuable due to their unexpected pharmacology, including effects on the network of SLC interactions, post-translational modifications, sub-cellular localization, or half-life – in addition to the canonical inhibition of substrate transport. (Schreiber, Israel J. Chem., 2019)

The RAPID platform is based on three core capabilities:


Jnana is using our RAPID platform to advance drug-discovery programs in our internal pipeline and in collaborations with biopharma partners to systematically target SLC transporters and develop small molecule therapeutics to treat a wide range of diseases.

Back to Top

This links to an external website. Merus is not responsible for any third party content.